Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. by Sciascia, S et al.
  
 
 
 
This is an author version of the contribution published on: 
 
Lupus an International Journal, vol. 20,  2011 
DOI:10.1177/0961203311400115 
S Sciascia, C Naretto, D Rossi, M Bazzan and D Roccatello, Sage Journal , 2011 
vol. 20 no. 10, pp. 1106-1108 
 
 
The definitive version is available at: 
http://lup.sagepub.com/ 
 
 
 
 
 
 
 
 
 
 Title page 
Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone 
on clinical and laboratory features of antiphospholipid syndrome 
 
Savino Sciascia
1
, Carla Naretto
1
, Daniela Rossi
1
, Mario Bazzan
2
 and  Dario Roccatello
1 
 
1
Centro di  Ricerche di Immunopatologia e Documentazione su Malattie Rare (CMID), SC a 
Direzione Universitaria di Immunologia Clinica, and 
2
SSD Ematologia, Dipartimento di Malattie 
Rare, Immunologiche, Ematologiche ed Immunoematologiche, Ospedale Torino Nord Emergenza-
San G. Bosco ed Università di Torino, Turin, Italy 
 
Address for correspondence:  
Dario Roccatello, Centro di  Ricerche di Immunopatologia e Documentazione su Malattie Rare 
(CMID), Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale Torino 
Nord Emergenza San G. Bosco ed Università di Torino, 
Piazza del Donatore di Sangue 3, 10154, Torino, Italy 
Email:dario.roccatello@unito.it  
phone 00390112402056 
fax 00390112402052 
 
 
 
 
 
 
 Sir, 
in 2000, a 20-year-old woman came to our attention with aphasia, transitory dysarthria, (CT-scan 
compatible with stroke) and thrombocytopenia (platelet-count 29×10
9
/l). Laboratory tests revealed: 
anticardiolipin antibodies (aCL, ELISA kit Phadia, Uppsala, Sweden, EliA Cardiolipin IgG/IgM, 
normal value <40 U/L ) 328/15 U/L, anti-beta-2GlycoproteinI antibodies (ELISA kit Phadia, 
Uppsala, Sweden, EliA ß2 Gliocprotein I IgG/IgM, normal value < 40 U/L )104/9U/L, and 
positivity for Lupus Anticoagulant (LAC). LAC measurement included: dilute Russell’s viper 
venom time (dRVVT, Hemosil, LA-screen/confirm, Instrumentation Laboratory, Lexington,USA), 
partial thromboplastin time-LA (PTT-LA, Diagnostica Stago, Asnieres,France), silica clotting time 
(SCT, HemosIL™, DiaPharma Group, Inc.Ohio, USA), kaoline clotting time (KCT, homemade, 
according to Exner) (1). If PTT-LA was prolonged, the hexagonal phospholipid neutralization test 
was performed as confirm (STACLOT-LA, Diagnostica STAGO, Asnières, France). Thus, a 
diagnosis of Primary Antiphospholipid Syndrome (PAPS) was made once  antiphospholipid 
antibody (aPL) positivity was confirmed 3 months later (2).  Therapy with prednisone (50mg/day) 
and intravenous immunoglobulins (IVIG, 400mg/kg/d for 5 days) was started resulting in an 
increase in platelet count. Oral anticoagulation therapy (OAT) was started  when the platelet-count 
reached 60×10
9
/l. Platelet levels increases up to 110x10
9
/l within 4 weeks and remained stable 
between 130 and 140 x10
9
/l for 4 months, when dropped again to 70 x 10
9
/l. Then the  patient was 
treated with adjusted doses of prednisone (37,5mg/day) and IVIG (400mg/kg/d for 5 more days). 
Prednisone treatment was slowly tapered to a daily dose of 7.5mg  and finally discontinued in May 
2007, when platelet counts were between 120 and 150x 10
9
/l.  
In 2009, she presented with a worsening of  thrombocytopenia (platelet count 40×10
9
/l) and she was 
treated with the same scheme of IVIG,  with partial response (platelet count up to 90×10
9
/l). She 
relapsed within 3 weeks.  Splenectomy was not performed due to the high risk of  thromboembolic 
and/or haemorrhagic  complications. 
After ruling out possible contraindications, treatment with Rituximab (RTX) was started at the 
conventional weekly-dose of 375 mg/m² (days1, 8, 15 and 22). Two more monthly doses later than 
the last infusion (day 22) were administered, based on the protocol we employ for mixed 
cryoglobulinemia with good results on long-lasting disease remission (3). Prednisone treatment 
(daily dose of 10 mg at day 1) was tapered and finally discontinued 4 weeks after first RTX-
infusion.  No other immunosuppressive drugs were associated. Treatment was well tolerated and no 
side effects were observed.  
RTX administration led to an increase in the platelet count (Fig.1). In addition,  aCL, anti Beta2-
GPI antibodies and LAC ratio were down-regulated (Fig.1). 
In this case, RTX-induced down-regulation of aPL was observed, and it was associated with a 
significant  improvement in thrombocytopenia, thus allowing OAT to be administered. 
Successful amelioration of thrombocytopenia in APS after treatment with immunosuppressive 
therapy has previously been reported (4). However, a non negligible percentage of patients becomes 
resistant/nonresponsive to immunosuppression,  and sometimes splenectomy cannot be performed 
because of the high risk of bleeding and/or thrombotic events. Some authors have reported that RTX 
is effective in treating APS  and reducing aPL(5) but drug-induced aPL downregulation remains a 
challenge (6). Notably, in a observational study in patients with Systemic Lupus Erythematosus  
RTX  resulted in a significant reduction in levels of IgG aCL (7) 
To our knowledge, this is the first report showing downregulation of aPL after RTX alone in a PAPS 
patient who was not treated with immunosuppressive drugs prior to anti-CD20 antibody therapy. 
Some Authors reported a close correlation between aCL titre reduction and an improvement in 
platelet count in patients with primary APS who were treated with RTX  for thrombocytopenia. 
However, these findings were observed in refractory cases following previous immunosuppressive 
drug administration in addition to RTX (8, 9, 10).  
Of note a 4 plus 2 protocol of Rituximab administration was employed (3). In our experience of  
treatment of idiopathic and secondary microscopic vasculitis, this scheme obtained more prolonged 
remissions, especially in mixed cryoglobulinemia where time to relapse was found delayed up to 54 
months. 
Morover,  it has been hypothesised  that B-cells are involved in the aPL-induced clinical 
manifestations of the disease (6 ) and it would be reasonable to  assume  that  RTX alone  (with no 
other immunosuppressant drug) may be useful in the management of APS. To date, after a 10-month 
follow-up period, the patient  is well and her platelet count is within the normal range. OAT is 
ongoing. 
Despite the limits related to the  relatively short follow-up, this report may represent  a starting 
point for further studies that could provide us with a better understanding of the mechanisms 
involved in  the pathogenesis of aPL production. 
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Figure 1 Legend 
RTX administration led to an increase in the platelet count (Panel A). In addition,  aCL, anti Beta2-
GPI antibodies (Panel A) and LAC ratio were down-regulated. (Panel B). LAC ratio: LAC screen 
(1:1)/LAC confirm (1:1). LAC measurement included: dilute Russell’s viper venom time (dRVVT, 
Hemosil, LA-screen/confirm, Instrumentation Laboratory, Lexington,USA), partial thromboplastin 
time-LA (PTT-LA, Diagnostica Stago, Asnieres,France), silica clotting time (SCT, HemosIL™, 
DiaPharma Group, Inc. Ohio, USA), kaoline clotting time (KCT, homemade, according to 
Exner)[3]. If PTT-LA was prolonged, the hexagonal phospholipid neutralization test was performed 
as confirm (STACLOT-LA, Diagnostica STAGO, Asnières,France). 
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